The Department of Justice is expected to reclassify cannabis to a less dangerous category, which would legitimize the industry, ease banking restrictions, and allow Tilray to bring its existing infrastructure, brands, and research to the U.S. market, potentially within six months, benefiting patients and the company's growth.